ANTEX BIOLOGICS INC
10QSB, EX-27.1, 2000-11-09
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ANTEX BIOLOGICS INC, 10QSB, EX-10.1, 2000-11-09
Next: CAPITAL AUTO RECEIVABLES INC, 10-Q, 2000-11-09



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                      12,319,036
<SECURITIES>                                         0
<RECEIVABLES>                                   93,876
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            12,528,850
<PP&E>                                       1,416,730
<DEPRECIATION>                               (594,890)
<TOTAL-ASSETS>                              13,524,581
<CURRENT-LIABILITIES>                        1,053,096
<BONDS>                                              0
                                0
                                        612
<COMMON>                                       109,601
<OTHER-SE>                                  12,271,523
<TOTAL-LIABILITY-AND-EQUITY>                13,524,581
<SALES>                                              0
<TOTAL-REVENUES>                               213,964
<CGS>                                                0
<TOTAL-COSTS>                                5,273,117
<OTHER-EXPENSES>                               330,068
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (4,729,145)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (4,729,145)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                            (4,729,145)
<CHANGES>                                            0
<NET-INCOME>                               (4,729,145)
<EPS-BASIC>                                     (0.70)
<EPS-DILUTED>                                   (0.70)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission